insulin glargine

New therapies show promise in treating diabetes
New therapies show promise in treating diabetesNew updates in insulin products, as well as non-pharma therapies are on the horizon for diabetes.
Insulin treatment persistence varies among payersA study from Walgreens provides a benchmark of basal insulin treatment persistence across different payers in the United States.
First “follow-on” insulin glargine product approved to treat diabetesFDA approved insulin glargine injection (Basaglar, Eli Lilly) to improve glycemic control in patients with diabetes mellitus.
Cholesterol-lowering agent leads list of most-prescribed drugsRosuvastatin (Crestor, AstraZeneca), a cholesterol-lowering agent, is currently the most-prescribed drug among the 100 most-prescribed and best-selling drugs in the United States. In the past 12 months, new prescriptions and refills for rosuvastatin have been estimated to amount to 23.7 million.
New data examines sustained glycemic control with exenatide once weekly vs. insulin glarginePost-hoc analysis found that, despite continued titration with insulin glargine, more diabetes patients achieved sustained glycemic control with exenatide once-weekly, according to data presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria.
ADA: Study says non-insulin dulaglutide demonstrates effective blood glucose control in diabetes patientsAmerican Diabetes Association Scientific Sessions in San Francisco, showed that investigational, non-insulin, once-weekly dulaglutide 1.5 mg provided significant blood glucose control for patients with type 2 diabetes.
ADA: Studies point to safety, efficacy profile for new insulin glargine productLY2963016 insulin glargine has a similar safety and efficacy profile to currently marketed insulin glargine, according to data recently presented the American Diabetes Association (ADA) Scientific Sessions in San Francisco.